FDA finalizes decision to keep impounded execution drugs from Texas justice system

The U.S. Food and Drug Administration will not release an intercepted shipment of hundreds of doses of sodium thiopental — an anesthetic used in executions — purchased by the Texas Department of Criminal Justice, according to a report from the Houston Chronicle.

Advertisement

The drugs, shipped by an unidentified foreign manufacturer, were seized by the FDA at Houston’s George Bush Intercontinental Airport in 2015, because they had not been approved by the agency for human use. The Texas department of justice subsequently filed a lawsuit against the FDA to force the agency to make decision as to whether or not to deliver the impounded drugs. The FDA filed documents in federal court April 20 stating it would not release the shipment to state officials.

U.S. drug manufacturers have long objected to the use of their products for the purposes of capital punishment. As these companies could not control how these products were used once introduced into the marketplace, many made the decision to take them out of the American market or cease making them entirely, according to the report. This has resulted in supply shortages of such drugs in states that impose the death penalty.

“It has taken almost two years for the FDA to reach a decision which we believe is flawed,” TDCJ spokesman Jason Clark said in a statement, according to the Chronicle. “TDCJ fully complied with the steps necessary to lawfully import the shipment. We are exploring all options to remedy the unjustified seizure.”

In another story that’s garnered national attention, Arkansas state authorities recently put plans into motion to execute eight inmates in 10 days in an effort to use the state’s supply of sodium thiopental before the drugs’ expiration date. Thus far, one of the executions has been carried out and four have been halted.

More articles on supply chain: 
Sanofi epilepsy drug linked to birth deformitie 
Marathon 2nd drugmaker to resign from PhRMA this month 
Survey: 99% of healthcare leaders concerned about drug price hikes

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

  • Abbott has launched an updated version of its Oncodetect blood test, which helps clinicians determine whether cancer remains in patients…

  • Becker’s asked supply chain leaders: If you had an extra $1 million for your supply chain budget, where would it…

  • As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…

Advertisement

Comments are closed.